The present invention provides a humanized anti-human α9 integrin antibody with improved activities and/or physical properties compared with a donor mouse anti-human α9 integrin antibody, i.e., providing a humanized anti-human α9 integrin antibody comprising heavy chain variable region formed by the amino acid sequence represented by Seq. No. 11 and the light chain variable region formed by the amino acid sequence represented by Seq. No. 17, a humanized anti-human α9 integrin antibody comprising heavy chain variable region formed by the amino acid sequence represented by Seq. No. 13 and the light chain variable region formed by the amino acid sequence represented by Seq. No. 17, a humanized anti-human α9 integrin antibody comprising heavy chain variable region formed by the amino acid sequence represented by Seq. No. 15 and the light chain variable region formed by the amino acid sequence represented by Seq. No. 9； and provides prophylactic and therapeutic means to morbid formations of various diseases involved in human α9 integrin antibody by using the said antibody.本發明提供與供與者小鼠抗人α9整連蛋白抗體相比較之下活性及/或物性被改善的人化抗人α9整連蛋白抗體，即，包含序列編號11所示胺基酸序列而成之重鏈可變區及序列編號17所示胺基酸序列而成之輕鏈可變區的人化抗人α9整連蛋白抗體，包含序列編號13所示胺基酸序列而成之重鏈可變區及序列編號17所示胺基酸序列而成之輕鏈可變區的人化抗人α9整連蛋白抗體，包含序列編號15所示胺基酸序列而成之重鏈可變區及序列編號9所示胺基酸序列而成之輕鏈可變區的人化抗人α9整連蛋白抗體；以及使用該抗體之人α9整連蛋白參與之病態形成的各種疾病之預防或治療手段。
